Direct pharmacological monitoring of the developmental switch in NMDA receptor subunit composition using TCN 213, a GluN2A‐selective, glycine‐dependent antagonist
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND PURPOSE: Developmental switches in NMDA receptor subunit expression have been inferred from studies of GluN2 expression levels, changes in kinetics of glutamatergic synaptic currents and sensitivity of NMDA receptor‐mediated currents to selective GluN2B antagonists. Here we use TCN 213, a novel GluN2A‐selective antagonist to identify the presence of this subunit in functional NMDA receptors in developing cortical neurones. EXPERIMENTAL APPROACH: Two‐electrode voltage‐clamp (TEVC) recordings were made from Xenopus laevis oocytes to determine the pharmacological activity of TCN 213 at recombinant NMDA receptors. TCN 213 antagonism was studied in cultures of primary cortical neurones, assessing the NMDA receptor dependency of NMDA‐induced excitotoxicity and monitoring developmental switches in NMDA receptor subunit composition. KEY RESULTS: TCN 213 antagonism of GluN1/GluN2A NMDA receptors was dependent on glycine but independent of glutamate concentrations in external recording solutions. Antagonism by TCN 213 was surmountable and gave a Schild plot with unity slope. TCN 213 block of GluN1/GluN2B NMDA receptor‐mediated currents was negligible. In cortical neurones, at a early developmental stage predominantly expressing GluN2B‐containing NMDA receptors, TCN 213 failed to antagonize NMDA receptor‐mediated currents or to prevent GluN2B‐dependent, NMDA‐induced excitoxicity. In older cultures (DIV 14) or in neurones transfected with GluN2A subunits, TCN 213 antagonized NMDA‐evoked currents. Block by TCN 213 of NMDA currents inversely correlated with block by ifenprodil, a selective GluN2B antagonist. CONCLUSIONS AND IMPLICATIONS: TCN 213 selectively blocked GluN1/GluN2A over GluN1/GluN2B NMDA receptors allowing direct dissection of functional NMDA receptors and pharmacological profiling of developmental changes in native NMDA receptor subunit composition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568 · cited 3×
“, 1994), and it is the identity of the GluN2 subunits contained within the tetrameric NMDA receptor complex that determines many of the distinct biophysical and pharmacological properties of NMDA receptor subtypes (see Erreger et al., 2004, Chen and Wyllie, 2006; Traynelis et al., 2010).”
BackgroundGuide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947 · cited 4×
“monitoring of the developmental switch in”
BackgroundInfluentialExtrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways
Hardingham, G. E., Fukunaga, Y., & Bading, H. (2002) · Nature Neuroscience · doi:10.1038/nn835 · Cited by 1,686 · cited 1×
“Such characteristics are indicative of necrotic, as opposed to apopotic, cell death (Fujikawa et al., 2000; Hardingham et al., 2002).”
BackgroundSelf-citationChanging subunit composition of heteromeric NMDA receptors during development of rat cortex
Sheng, M., Cummings, J., Roldan, L. A., Jan, Y. N., & Jan, L. Y. (1994) · Nature · doi:10.1038/368144a0 · Cited by 1,377
Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses
Papadia, S., Soriano, F. X., Léveillé, F., Martel, M.-A., Dakin, K. A., Hansen, H. H., Kaindl, A., Sifringer, M., Fowler, J., Stefovska, V., et al. (2008) · Nature Neuroscience · doi:10.1038/nn2071 · Cited by 498 · cited 2×
“Culture of rat cortical neurones Cortical neurones from E21 Sprague–Dawley rat embryos were cultured as described previously (Bading and Greenberg, 1991; Papadia et al., 2008; Martel et al., 2009), except that the Neurobasal-A growth medium contained B27 (Invitrogen), 1% rat serum (Harlan UK Ltd.”
MethodSelf-citation
Cited by
NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease
Paoletti, P., Bellone, C., & Zhou, Q. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3504 · Cited by 2,523
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686
Influence of GluN2 subunit identity on NMDA receptor function
Wyllie, D. J. A., Livesey, M. R., & Hardingham, G. E. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.01.016 · Cited by 260
“…and related allosteric inhibitors decreases, consistent with the increased expression of GluN2A subunits and the presence of a substantial population of native GluN1/GluN2A/GluN2B NMDARs (see for example Edman et al. (2012), Gray et al. (2011), McKay et al. (2012), Rauner and Kohr (2011)).”
BackgroundInfluentialSelf-citationPerszyk, R. E., DiRaddo, J. O., Strong, K. L., Low, C.-M., Ogden, K. K., Khatri, A., Vargish, G. A., Pelkey, K. A., Tricoire, L., Liotta, D. C., et al. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.105130 · Cited by 116
Fedele, L., Newcombe, J., Topf, M., Gibb, A., Harvey, R. J., & Smart, T. G. (2018) · Nature Communications · doi:10.1038/s41467-018-02927-4 · Cited by 82
Metadata
- Authors
- McKay, S., Griffiths, N., Butters, P., Thubron, E., Hardingham, G., & Wyllie, D.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2012-05-08
- Volume
- 166
- Issue
- 3
- Pages
- 924-937
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1888844436
- Cited by
- 39
- References
- 5
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.